Utah People's Post

The Latest News from the Beehive State

Friday, January 15, 2021
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / AstraZeneca May Have Found a Way to Tackle Lung Cancer

AstraZeneca May Have Found a Way to Tackle Lung Cancer

Posted by

032213_astrazeneca_600

Medical studies are often inconclusive, but even the smallest advancements can prove invaluable for humanity. AstraZeneca seems to have found a way to tackle lung cancer with the help of a newly developed combination of drugs. Tests are still inconclusive, but medics are optimistic because it seems that the new drugs will also boost the immune system.

After having avoided a multi-billion dollar takeover from Pfizer, AstraZeneca continued to focus on its experiments. One of them was the drug combination project for combating lung cancer. This new drug combination is called MEDIA736 and tremelimumab. Although the substances which supposedly treat lung cancer have been discovered, scientists still do not know what type of dose a patient needs.

But dosages aren’t the only factors that remain unknown. Scientists have no idea if there are any side effects to the new drugs. If there are any, will they emerge benign or life-threatening? The ESMO (European Society for Medical Oncology) was the event where the new drug combination was announced. According to official reports, only 24 patients have been treated with the drug until now, but the results look promising. Pascal Soriot, chief of ESMO, declared earlier that the numbers for the experimentation phase will be limited.

This means that it might take a while until we find out whether or not the two drugs are actually effective in the fight against lung cancer. On the bright side, the results of the drug combination has not only proved to be effective in dealing with cancer, but it also appears to be a safe solution.

At the moment, new experiments are underway and we can only wait and see if AstraZeneca’s MEDIA 736 and tremelimumab drugs are actually all they’re cracked up to be. At the moment, Pfizer is still waiting to to takeover the company, but UK laws dictate that they have to wait another three months before they attempt a new takeover.

At first, AstraZeneca balked at the price that Pfizer put on the table. Now, they may gain the upper-hand. If the new drug proves effective, the price per stock may raise significantly, and alter the one that was originally offered by Pfizer (118$ billion). Pfizer may end up having to offer far more than it originally intended to. A treatment for lung cancer would be extremely welcome especially since lung cancer is the number one killer in patients wit cancer.

Also, studies have yet to reveal how the drug is administered (in one treatment or over time). More data will be made public in the following months (or years), but if AstraZeneca is successful, the new drug will mean a great step forward for humanity.

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health Tagged With: astrazeneca lung cancer, astrazeneca takeover, lung cancer, lung cancer cure, lung cancer treatment

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

By

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

By

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

By

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

By

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

By

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

By

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

By

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

By

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

By

456 People Dead at U.K. Hospital after Taking too Many Painkillers

By

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

By

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2021 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This website uses cookies to ensure you get the best experience on our website. Learn more.